NanosiRNA® COVID-19: specific antiviral treatment
Medesis Pharma has a microemulsion technology that enables it to deliver these non-modified native siRNAs directly into the cytoplasm of all the organism’s cells via the HDL lipoprotein receptors, crossing the blood–brain barrier (BBB) after a non-invasive oral administration.
One very important factor for clinical development: the siRNA is invisible from the mouth through to delivery into the cells’ cytoplasm for the entire immune system because it is included in the lipoproteins, and we do not trigger any immune response.
A randomized, placebo-controlled, parallel-group, double-blind phase 2 trial is currently being prepared to assess the clinical efficacy of NanosiRNA® alongside standard treatments for proven symptomatic COVID-19 adult patients at general practice level.